TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
HEIDELBERG, Germany, Feb. 22, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CMO, Jens-Peter Marschner, will present at the symposium titled "Emerging Approaches in Cancer Immunotherapy" in New York City on Monday, February 29 at 12:10-12:40 pm Eastern Standard Time. The symposium will be presented as part of the New York Academy of Sciences' Cancer and Signaling Discussion Group, which provides a forum for scientists from academia, industry, and government, as well as other stakeholders, to come together to explore cutting-edge topics in the field. A live webcast of Affimed's presentation will be available through the New York Academy of Sciences' website at www.nyas.org.
About Affimed N.V.
Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head of IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
